Gain Therapeutics(GANX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update Initiation of Phase 1b Study of GT-02287 in Parkinson's patients expected by end of 2024 BETHESDA, Md., November 14, 2024 -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 20 ...